Alterity Therapeutics (ASX:ATH): CEO Dr David Stamler on ATH434, FDA Phase 3 & the Quest to Treat Multiple System Atrophy

Can Alterity Therapeutics (ASX:ATH) become the first company to develop a disease-modifying treatment for Multiple System Atrophy (MSA)? In this episode of the Homodeus Research Podcast, Dr David Stamler, Managing Director & CEO of Alterity Therapeutics, discusses the company's lead therapeutic candidate, ATH434, and the latest progress toward a pivotal Phase 3 clinical trial following alignment with the U.S. Food and Drug Administration (FDA). Dr Stamler explains the underlying science behind ATH434, how abnormal iron accumulation contributes to neurodegenerative disease, and why Alterity believes its therapy has the potential to slow disease progression rather than simply manage symptoms. The discussion explores recent clinical data, biomarker results, the significance of the FDA's feedback on the Phase 3 registration pathway, the recently granted U.S. composition-of-matter patent, commercial opportunities in rare neurological diseases, and the key milestones investors should watch over the coming years. Whether you're an investor interested in biotechnology, neuroscience or ASX healthcare companies, this episode provides a comprehensive overview of Alterity's science, regulatory strategy and long-term growth potential. Topics Covered - Overview of Alterity Therapeutics - Understanding Multiple System Atrophy (MSA) - How ATH434 works - FDA agreement on the Phase 3 registration study - Clinical trial and biomarker results - The significance of the new U.S. patent - Commercial opportunity for disease-modifying therapies - Pipeline and future development strategy - Key regulatory and clinical catalysts - Live investor Q&A